Bal Pharma Limited (BALPHARMA.BO)
INR 106.04
(1.49%)
INR 106.04
(1.49%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.26 Billion INR | -3.98% |
| 2022 | 1.31 Billion INR | 24.68% |
| 2021 | 1.05 Billion INR | -4.85% |
| 2020 | 1.1 Billion INR | -7.22% |
| 2019 | 1.19 Billion INR | -1.24% |
| 2018 | 1.21 Billion INR | 13.33% |
| 2017 | 1.06 Billion INR | 17.45% |
| 2016 | 909.49 Million INR | 4.54% |
| 2015 | 869.97 Million INR | 110.71% |
| 2014 | 412.87 Million INR | -13.44% |
| 2013 | 476.95 Million INR | 14.94% |
| 2012 | 414.97 Million INR | -12.81% |
| 2011 | 475.93 Million INR | -6.81% |
| 2010 | 510.73 Million INR | -3.57% |
| 2009 | 529.66 Million INR | 15.63% |
| 2008 | 458.07 Million INR | 8.42% |
| 2007 | 422.48 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q4 | 1.26 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 1.39 Billion INR | 0.0% |
| 2023 FY | 1.26 Billion INR | -3.98% |
| 2022 Q4 | 1.31 Billion INR | 0.0% |
| 2022 FY | 1.31 Billion INR | 24.68% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 1.36 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 994.96 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 1.05 Billion INR | -4.85% |
| 2021 Q4 | 1.05 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q2 | 1.15 Billion INR | 0.0% |
| 2020 FY | 1.1 Billion INR | -7.22% |
| 2020 Q4 | 1.1 Billion INR | 0.0% |
| 2019 FY | 1.19 Billion INR | -1.24% |
| 2019 Q2 | 1.13 Billion INR | 0.0% |
| 2019 Q4 | 1.19 Billion INR | 0.0% |
| 2018 Q4 | 1.21 Billion INR | 0.0% |
| 2018 FY | 1.21 Billion INR | 13.33% |
| 2017 Q4 | 1.06 Billion INR | 0.0% |
| 2017 FY | 1.06 Billion INR | 17.45% |
| 2016 Q2 | 787.93 Million INR | 0.0% |
| 2016 Q4 | 909.49 Million INR | 0.0% |
| 2016 FY | 909.49 Million INR | 4.54% |
| 2015 Q2 | 634.28 Million INR | 0.0% |
| 2015 Q4 | 869.97 Million INR | 0.0% |
| 2015 FY | 869.97 Million INR | 110.71% |
| 2014 FY | 412.87 Million INR | -13.44% |
| 2014 Q2 | 423.07 Million INR | 0.0% |
| 2014 Q4 | 412.87 Million INR | 0.0% |
| 2013 Q2 | 439.72 Million INR | 0.0% |
| 2013 FY | 476.95 Million INR | 14.94% |
| 2013 Q4 | 476.95 Million INR | 0.0% |
| 2012 Q2 | 441.78 Million INR | 0.0% |
| 2012 Q4 | 414.97 Million INR | 0.0% |
| 2012 FY | 414.97 Million INR | -12.81% |
| 2011 Q4 | 475.93 Million INR | 0.0% |
| 2011 FY | 475.93 Million INR | -6.81% |
| 2010 FY | 510.73 Million INR | -3.57% |
| 2009 FY | 529.66 Million INR | 15.63% |
| 2008 FY | 458.07 Million INR | 8.42% |
| 2007 FY | 422.48 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 101.744% |
| NATCO Pharma Limited | -5.81 Billion INR | 121.722% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -771.566% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -2634.329% |
| Achyut Healthcare Limited | -3.74 Million INR | 33830.94% |
| Ajanta Pharma Limited | -954.9 Million INR | 232.324% |
| Alkem Laboratories Limited | -1.6 Billion INR | 178.511% |
| Alpa Laboratories Limited | 35.36 Million INR | -3473.116% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 67.315% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 125.208% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 65.788% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 61.698% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 209.139% |
| Brooks Laboratories Limited | 49.48 Million INR | -2453.422% |
| Divi's Laboratories Limited | -39.77 Billion INR | 103.177% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 90.215% |
| Eris Lifesciences Limited | 13.8 Billion INR | 90.848% |
| FDC Limited | -57.75 Million INR | 2287.909% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 129.486% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 144.45% |
| Granules India Limited | 9.28 Billion INR | 86.394% |
| Gufic Biosciences Limited | 3.19 Billion INR | 60.443% |
| Hester Biosciences Limited | 2.29 Billion INR | 44.84% |
| Indoco Remedies Limited | 6.47 Billion INR | 80.489% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 130.425% |
| Ipca Laboratories Limited | 11.41 Billion INR | 88.931% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 190.908% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 34.629% |
| Lasa Supergenerics Limited | 205.79 Million INR | -513.978% |
| Laurus Labs Limited | 24.38 Billion INR | 94.818% |
| Lupin Limited | 17.19 Billion INR | 92.65% |
| Mankind Pharma Limited | -9.9 Billion INR | 112.753% |
| Medicamen Biotech Limited | 160.31 Million INR | -688.169% |
| Medico Remedies Limited | 78.67 Million INR | -1506.011% |
| Megasoft Limited | 1.28 Billion INR | 1.711% |
| Piramal Pharma Limited | 42.27 Billion INR | 97.011% |
| RPG Life Sciences Limited | -364.7 Million INR | 446.466% |
| Sigachi Industries Limited | 859.94 Million INR | -46.934% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 234.164% |
| Unichem Laboratories Limited | 931.91 Million INR | -35.587% |
| Wanbury Limited | 1.1 Billion INR | -14.259% |
| Windlas Biotech Limited | -273.04 Million INR | 562.775% |
| ZIM Laboratories Limited | 983.6 Million INR | -28.462% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 67.7% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 153.814% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 607.878% |
| Strides Pharma Science Limited | 23.25 Billion INR | 94.567% |
| Venus Remedies Limited | -267.7 Million INR | 572.006% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 51.623% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 79.479% |
| Shilpa Medicare Limited | 9.06 Billion INR | 86.068% |
| Aarti Drugs Limited | 5.54 Billion INR | 77.227% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 214.734% |
| Suven Life Sciences Limited | -1.63 Billion INR | 177.391% |
| Ind-Swift Limited | 9.5 Billion INR | 86.711% |
| Valiant Laboratories Limited | -295.03 Million INR | 528.279% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 55.212% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 87.401% |
| Themis Medicare Limited | 764.96 Million INR | -65.18% |
| Hikal Limited | 7.96 Billion INR | 84.14% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 96.03% |
| Sequent Scientific Limited | 4.17 Billion INR | 69.761% |
| Novartis India Limited | -5.89 Billion INR | 121.449% |
| Wockhardt Limited | 18.27 Billion INR | 93.084% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 95.333% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 6950.054% |
| Neuland Laboratories Limited | -214.05 Million INR | 690.289% |
| Morepen Laboratories Limited | -231.17 Million INR | 646.584% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -952.625% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -29.488% |